- Home
- JBLU vs RCKT Comparison
JBLU vs RCKT Comparison
Compare JBLU & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- RCKT
- Stock Information
- Founded
- JBLU 1998
- RCKT 1999
- Country
- JBLU United States
- RCKT United States
- Employees
- JBLU N/A
- RCKT N/A
- Industry
- JBLU Air Freight/Delivery Services
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- JBLU Consumer Discretionary
- RCKT Health Care
- Exchange
- JBLU Nasdaq
- RCKT Nasdaq
- Market Cap
- JBLU 1.5B
- RCKT 264.0M
- IPO Year
- JBLU N/A
- RCKT N/A
- Fundamental
- Price
- JBLU $4.33
- RCKT $2.81
- Analyst Decision
- JBLU Sell
- RCKT Buy
- Analyst Count
- JBLU 11
- RCKT 13
- Target Price
- JBLU $4.97
- RCKT $18.50
- AVG Volume (30 Days)
- JBLU 18.7M
- RCKT 3.6M
- Earning Date
- JBLU 07-29-2025
- RCKT 08-04-2025
- Dividend Yield
- JBLU N/A
- RCKT N/A
- EPS Growth
- JBLU N/A
- RCKT N/A
- EPS
- JBLU N/A
- RCKT N/A
- Revenue
- JBLU $9,210,000,000.00
- RCKT N/A
- Revenue This Year
- JBLU N/A
- RCKT N/A
- Revenue Next Year
- JBLU $7.84
- RCKT N/A
- P/E Ratio
- JBLU N/A
- RCKT N/A
- Revenue Growth
- JBLU N/A
- RCKT N/A
- 52 Week Low
- JBLU $3.34
- RCKT $2.19
- 52 Week High
- JBLU $8.31
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- JBLU 47.61
- RCKT 41.85
- Support Level
- JBLU $4.30
- RCKT $2.76
- Resistance Level
- JBLU $4.81
- RCKT $3.24
- Average True Range (ATR)
- JBLU 0.20
- RCKT 0.19
- MACD
- JBLU 0.03
- RCKT 0.13
- Stochastic Oscillator
- JBLU 39.29
- RCKT 49.10
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.